BiotechTube

SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + Febuxostat

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Gout and Hyperuricemia

Conditions

Primary Gout and Hyperuricemia

Trial Timeline

Feb 1, 2026 → Jul 1, 2027

NCT ID
NCT07362355

About SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + Febuxostat

SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + Febuxostat is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Primary Gout and Hyperuricemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07362355. Target conditions include Primary Gout and Hyperuricemia.

What happened to similar drugs?

20 of 20 similar drugs in Primary Gout and Hyperuricemia were approved

Approved (20) Terminated (6) Active (0)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Duloxetine + PlaceboEli LillyApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07362355Phase 2Recruiting

Competing Products

20 competing products in Primary Gout and Hyperuricemia

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31